Identification of KW-2449 as a dual inhibitor of ferroptosis and necroptosis reveals that autophagy is a targetable pathway for necroptosis inhibitors to prevent ferroptosis.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
21 Oct 2024
Historique:
received: 19 03 2024
accepted: 14 10 2024
revised: 10 10 2024
medline: 22 10 2024
pubmed: 22 10 2024
entrez: 21 10 2024
Statut: epublish

Résumé

Necroptosis and ferroptosis are two distinct forms of necrotic-like cell death in terms of their morphological features and regulatory mechanisms. These two types of cell death can coexist in disease and contribute to pathological processes. Inhibition of both necroptosis and ferroptosis has been shown to enhance therapeutic effects in treating complex necrosis-related diseases. However, targeting both necroptosis and ferroptosis by a single compound can be challenging, as these two forms of cell death involve distinct molecular pathways. In this study, we discovered that KW-2449, a previously described necroptosis inhibitor, also prevented ferroptosis both in vitro and in vivo. Mechanistically, KW-2449 inhibited ferroptosis by targeting the autophagy pathway. We further identified that KW-2449 functioned as a ULK1 (Unc-51-like kinase 1) inhibitor to block ULK1 kinase activity in autophagy. Remarkably, we found that Necrostatin-1, a classic necroptosis inhibitor that has been shown to prevent ferroptosis, also targets the autophagy pathway to suppress ferroptosis. This study provides the first understanding of how necroptosis inhibitors can prevent ferroptosis and suggests that autophagy is a targetable pathway for necroptosis inhibitors to prevent ferroptosis. Therefore, the identification and design of pharmaceutical molecules that target the autophagy pathway from necroptosis inhibitors is a promising strategy to develop dual inhibitors of necroptosis and ferroptosis in clinical application.

Identifiants

pubmed: 39433736
doi: 10.1038/s41419-024-07157-9
pii: 10.1038/s41419-024-07157-9
doi:

Substances chimiques

Autophagy-Related Protein-1 Homolog EC 2.7.11.1
necrostatin-1 0
Imidazoles 0
Indoles 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

764

Subventions

Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 32170748
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82204481
Organisme : Shanghai Science and Technology Development Foundation (Shanghai Science and Technology Development Fund)
ID : 21490714300
Organisme : Natural Science Foundation of Shanghai (Natural Science Foundation of Shanghai Municipality)
ID : 22ZR1448000

Informations de copyright

© 2024. The Author(s).

Références

Fuchs Y, Steller H. Programmed cell death in animal development and disease. Cell. 2011;147:742–58.
pubmed: 22078876 doi: 10.1016/j.cell.2011.10.033
Yuan J, Ofengeim D. A guide to cell death pathways. Nat Rev Mol Cell Biol. 2024;25:379–95.
pubmed: 38110635 doi: 10.1038/s41580-023-00689-6
Ai Y, Meng Y, Yan B, Zhou Q, Wang X. The biochemical pathways of apoptotic, necroptotic, pyroptotic, and ferroptotic cell death. Mol Cell. 2024;84:170–9.
pubmed: 38181758 doi: 10.1016/j.molcel.2023.11.040
Conrad M, Angeli JP, Vandenabeele P, Stockwell BR. Regulated necrosis: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 2016;15:348–66.
pubmed: 26775689 pmcid: 6531857 doi: 10.1038/nrd.2015.6
Yan J, Wan P, Choksi S, Liu ZG. Necroptosis and tumor progression. Trends Cancer. 2022;8:21–7.
pubmed: 34627742 doi: 10.1016/j.trecan.2021.09.003
Weinlich R, Oberst A, Beere HM, Green DR. Necroptosis in development, inflammation and disease. Nat Rev Mol Cell Biol. 2017;18:127–36.
pubmed: 27999438 doi: 10.1038/nrm.2016.149
Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266–82.
pubmed: 33495651 pmcid: 8142022 doi: 10.1038/s41580-020-00324-8
Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35:830–49.
pubmed: 31105042 doi: 10.1016/j.ccell.2019.04.002
Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26:165–76.
pubmed: 26653790 doi: 10.1016/j.tcb.2015.10.014
Liu J, Kuang F, Kroemer G, Klionsky DJ, Kang R, Tang D. Autophagy-dependent ferroptosis: machinery and regulation. Cell Chem Biol. 2020;27:420–35.
pubmed: 32160513 pmcid: 7166192 doi: 10.1016/j.chembiol.2020.02.005
Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. Ferroptosis is an autophagic cell death process. Cell Res. 2016;26:1021–32.
pubmed: 27514700 pmcid: 5034113 doi: 10.1038/cr.2016.95
Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ 3rd, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 2016;12:1425–8.
pubmed: 27245739 pmcid: 4968231 doi: 10.1080/15548627.2016.1187366
Bai Y, Meng L, Han L, Jia Y, Zhao Y, Gao H, et al. Lipid storage and lipophagy regulates ferroptosis. Biochem Biophys Res Commun. 2019;508:997–1003.
pubmed: 30545638 doi: 10.1016/j.bbrc.2018.12.039
Yang M, Chen P, Liu J, Zhu S, Kroemer G, Klionsky DJ, et al. Clockophagy is a novel selective autophagy process favoring ferroptosis. Sci Adv. 2019;5:eaaw2238.
pubmed: 31355331 pmcid: 6656546 doi: 10.1126/sciadv.aaw2238
Wu Z, Geng Y, Lu X, Shi Y, Wu G, Zhang M, et al. Chaperone-mediated autophagy is involved in the execution of ferroptosis. Proc Natl Acad Sci USA. 2019;116:2996–3005.
pubmed: 30718432 pmcid: 6386716 doi: 10.1073/pnas.1819728116
Zhou Y, Liao J, Mei Z, Liu X, Ge J. Insight into crosstalk between ferroptosis and necroptosis: novel therapeutics in ischemic stroke. Oxid Med Cell Longev. 2021;2021:9991001.
pubmed: 34257829 pmcid: 8257382 doi: 10.1155/2021/9991001
Moujalled D, Strasser A, Liddell JR. Molecular mechanisms of cell death in neurological diseases. Cell Death Differ. 2021;28:2029–44.
pubmed: 34099897 pmcid: 8257776 doi: 10.1038/s41418-021-00814-y
Pefanis A, Ierino FL, Murphy JM, Cowan PJ. Regulated necrosis in kidney ischemia-reperfusion injury. Kidney Int. 2019;96:291–301.
pubmed: 31005270 doi: 10.1016/j.kint.2019.02.009
Belavgeni A, Meyer C, Stumpf J, Hugo C, Linkermann A. Ferroptosis and necroptosis in the kidney. Cell Chem Biol. 2020;27:448–62.
pubmed: 32302582 doi: 10.1016/j.chembiol.2020.03.016
Linkermann A, Skouta R, Himmerkus N, Mulay SR, Dewitz C, De Zen F, et al. Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci USA. 2014;111:16836–41.
pubmed: 25385600 pmcid: 4250130 doi: 10.1073/pnas.1415518111
Muller T, Dewitz C, Schmitz J, Schroder AS, Brasen JH, Stockwell BR, et al. Necroptosis and ferroptosis are alternative cell death pathways that operate in acute kidney failure. Cell Mol Life Sci. 2017;74:3631–45.
pubmed: 28551825 pmcid: 5589788 doi: 10.1007/s00018-017-2547-4
Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16:1180–91.
pubmed: 25402683 doi: 10.1038/ncb3064
Yuk H, Abdullah M, Kim DH, Lee H, Lee SJ. Necrostatin-1 prevents ferroptosis in a RIPK1- and IDO-independent manner in hepatocellular carcinoma. Antioxidants (Basel). 2021;10:1347.
pubmed: 34572979 doi: 10.3390/antiox10091347
Tonnus W, Meyer C, Steinebach C, Belavgeni A, von Massenhausen A, Gonzalez NZ, et al. Dysfunction of the key ferroptosis-surveilling systems hypersensitizes mice to tubular necrosis during acute kidney injury. Nat Commun. 2021;12:4402.
pubmed: 34285231 pmcid: 8292346 doi: 10.1038/s41467-021-24712-6
Delehouze C, Comte A, Leon-Icaza SA, Cougoule C, Hauteville M, Goekjian P, et al. Nigratine as dual inhibitor of necroptosis and ferroptosis regulated cell death. Sci Rep. 2022;12:5118.
pubmed: 35332201 pmcid: 8944179 doi: 10.1038/s41598-022-09019-w
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMJ Open Sci. 2020;4:e100115.
pubmed: 34095516 pmcid: 7610906
Rui C, Shi SN, Ren W, Qin X, Zhuang C, Chen X, et al. The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis. Biochem Pharmacol. 2021;188:114542.
pubmed: 33819469 doi: 10.1016/j.bcp.2021.114542
Van Coillie S, Van San E, Goetschalckx I, Wiernicki B, Mukhopadhyay B, Tonnus W, et al. Targeting ferroptosis protects against experimental (multi)organ dysfunction and death. Nat Commun. 2022;13:1046.
pubmed: 35210435 pmcid: 8873468 doi: 10.1038/s41467-022-28718-6
Yee PP, Wei Y, Kim SY, Lu T, Chih SY, Lawson C, et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nat Commun. 2020;11:5424.
pubmed: 33110073 pmcid: 7591536 doi: 10.1038/s41467-020-19193-y
Xu Y, Ma H, Shao J, Wu J, Zhou L, Zhang Z, et al. A role for tubular necroptosis in cisplatin-induced AKI. J Am Soc Nephrol. 2015;26:2647–58.
pubmed: 25788533 pmcid: 4625668 doi: 10.1681/ASN.2014080741
Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185:2401–21.
pubmed: 35803244 pmcid: 9273022 doi: 10.1016/j.cell.2022.06.003
Kuang F, Liu J, Tang D, Kang R. Oxidative damage and antioxidant defense in ferroptosis. Front Cell Dev Biol. 2020;8:586578.
pubmed: 33043019 pmcid: 7527737 doi: 10.3389/fcell.2020.586578
Liu J, Li X, Chen J, Zhang X, Guo J, Gu J, et al. Arsenic-loaded biomimetic iron oxide nanoparticles for enhanced ferroptosis-inducing therapy of hepatocellular carcinoma. ACS Appl Mater Interfaces. 2023;15:6260–73.
pubmed: 36695492 doi: 10.1021/acsami.2c14962
Dai Z, Zhang W, Zhou L, Huang J. Probing lipid peroxidation in ferroptosis: emphasizing the utilization of C11-BODIPY-based protocols. Methods Mol Biol. 2023;2712:61–72.
pubmed: 37578696 doi: 10.1007/978-1-0716-3433-2_6
Shiotsu Y, Kiyoi H, Ishikawa Y, Tanizaki R, Shimizu M, Umehara H, et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009;114:1607–17.
pubmed: 19541823 doi: 10.1182/blood-2009-01-199307
Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1). Autophagy. 2021;17:1–382.
pubmed: 33634751 pmcid: 7996087 doi: 10.1080/15548627.2020.1797280
Eskelinen EL. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Mol Aspects Med. 2006;27:495–502.
pubmed: 16973206 doi: 10.1016/j.mam.2006.08.005
Araujo TF, Cordeiro AV, Vasconcelos DAA, Vitzel KF, Silva VRR. The role of cathepsin B in autophagy during obesity: a systematic review. Life Sci. 2018;209:274–81.
pubmed: 30107168 doi: 10.1016/j.lfs.2018.08.024
Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature. 2014;509:105–9.
pubmed: 24695223 pmcid: 4180099 doi: 10.1038/nature13148
Dowdle WE, Nyfeler B, Nagel J, Elling RA, Liu S, Triantafellow E, et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat Cell Biol. 2014;16:1069–79.
pubmed: 25327288 doi: 10.1038/ncb3053
Andrews NC, Schmidt PJ. Iron homeostasis. Annu Rev Physiol. 2007;69:69–85.
pubmed: 17014365 doi: 10.1146/annurev.physiol.69.031905.164337
Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, et al. Autophagy regulates lipid metabolism. Nature. 2009;458:1131–5.
pubmed: 19339967 pmcid: 2676208 doi: 10.1038/nature07976
Bailey AP, Koster G, Guillermier C, Hirst EM, MacRae JI, Lechene CP, et al. Antioxidant role for lipid droplets in a stem cell niche of Drosophila. Cell. 2015;163:340–53.
pubmed: 26451484 pmcid: 4601084 doi: 10.1016/j.cell.2015.09.020
Mizushima N, Yamamoto A, Hatano M, Kobayashi Y, Kabeya Y, Suzuki K, et al. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol. 2001;152:657–68.
pubmed: 11266458 pmcid: 2195787 doi: 10.1083/jcb.152.4.657
Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science. 2011;331:456–61.
pubmed: 21205641 doi: 10.1126/science.1196371
Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132–41.
pubmed: 21258367 pmcid: 3987946 doi: 10.1038/ncb2152
Yu L, Chen Y, Tooze SA. Autophagy pathway: cellular and molecular mechanisms. Autophagy. 2018;14:207–15.
pubmed: 28933638 doi: 10.1080/15548627.2017.1378838
Park JM, Jung CH, Seo M, Otto NM, Grunwald D, Kim KH, et al. The ULK1 complex mediates MTORC1 signaling to the autophagy initiation machinery via binding and phosphorylating ATG14. Autophagy. 2016;12:547–64.
pubmed: 27046250 pmcid: 4835982 doi: 10.1080/15548627.2016.1140293
Lazarus MB, Novotny CJ, Shokat KM. Structure of the human autophagy initiating kinase ULK1 in complex with potent inhibitors. ACS Chem Biol. 2015;10:257–61.
pubmed: 25551253 doi: 10.1021/cb500835z
Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1:112–9.
pubmed: 16408008 doi: 10.1038/nchembio711
Kabir A, Muth A. Polypharmacology: the science of multi-targeting molecules. Pharmacol Res. 2022;176:106055.
pubmed: 34990865 doi: 10.1016/j.phrs.2021.106055
Pratz KW, Cortes J, Roboz GJ, Rao N, Arowojolu O, Stine A, et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood. 2009;113:3938–46.
pubmed: 19029442 pmcid: 2673122 doi: 10.1182/blood-2008-09-177030
Liu Y, Yang EJ, Zhang B, Miao Z, Wu C, Lyu J, et al. PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A. Cancer Lett. 2018;436:28–37.
pubmed: 30118842 doi: 10.1016/j.canlet.2018.08.011
Napoletano F, Baron O, Vandenabeele P, Mollereau B, Fanto M. Intersections between regulated cell death and autophagy. Trends Cell Biol. 2019;29:323–38.
pubmed: 30665736 doi: 10.1016/j.tcb.2018.12.007
Xue Q, Yan D, Chen X, Li X, Kang R, Klionsky DJ, et al. Copper-dependent autophagic degradation of GPX4 drives ferroptosis. Autophagy. 2023;19:1982–96.
pubmed: 36622894 pmcid: 10283421 doi: 10.1080/15548627.2023.2165323
Li J, Liu J, Xu Y, Wu R, Chen X, Song X, et al. Tumor heterogeneity in autophagy-dependent ferroptosis. Autophagy. 2021;17:3361–74.
pubmed: 33404288 pmcid: 8632302 doi: 10.1080/15548627.2021.1872241
Chen X, Song X, Li J, Zhang R, Yu C, Zhou Z, et al. Identification of HPCAL1 as a specific autophagy receptor involved in ferroptosis. Autophagy. 2023;19:54–74.
pubmed: 35403545 doi: 10.1080/15548627.2022.2059170
Matsuzawa-Ishimoto Y, Shono Y, Gomez LE, Hubbard-Lucey VM, Cammer M, Neil J, et al. Autophagy protein ATG16L1 prevents necroptosis in the intestinal epithelium. J Exp Med. 2017;214:3687–705.
pubmed: 29089374 pmcid: 5716041 doi: 10.1084/jem.20170558
Xie Y, Zhao Y, Shi L, Li W, Chen K, Li M, et al. Gut epithelial TSC1/mTOR controls RIPK3-dependent necroptosis in intestinal inflammation and cancer. J Clin Invest. 2020;130:2111–28.
pubmed: 31961824 pmcid: 7108921 doi: 10.1172/JCI133264
Goodall ML, Fitzwalter BE, Zahedi S, Wu M, Rodriguez D, Mulcahy-Levy JM, et al. The autophagy machinery controls cell death switching between apoptosis and necroptosis. Dev Cell. 2016;37:337–49.
pubmed: 27219062 pmcid: 4886731 doi: 10.1016/j.devcel.2016.04.018
Wu X, Poulsen KL, Sanz-Garcia C, Huang E, McMullen MR, Roychowdhury S, et al. MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcohol-associated fatty liver and steatohepatitis. J Hepatol. 2020;73:616–27.
pubmed: 32220583 pmcid: 7438259 doi: 10.1016/j.jhep.2020.03.023

Auteurs

Yaxing Zhao (Y)

Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.

Qingsong Wang (Q)

College of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, Yinchuan, China.

Jing Zhu (J)

Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Department of Biochemistry and Molecular Biology, School of Medicine, Tongji University, Shanghai, China.

Jin Cai (J)

Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Department of Biochemistry and Molecular Biology, School of Medicine, Tongji University, Shanghai, China.

Xiaona Feng (X)

College of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, Yinchuan, China.

Qianqian Song (Q)

Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Department of Biochemistry and Molecular Biology, School of Medicine, Tongji University, Shanghai, China.

Hui Jiang (H)

Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Department of Biochemistry and Molecular Biology, School of Medicine, Tongji University, Shanghai, China.

Wenqing Ren (W)

Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.

Yuan He (Y)

Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.

Ping Wang (P)

Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.

Du Feng (D)

Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China.

Jianqiang Yu (J)

College of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, Yinchuan, China.

Yue Liu (Y)

College of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, Yinchuan, China.

Qihui Wu (Q)

Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.

Jitkaew Siriporn (J)

Center of Excellence for Cancer and Inflammation, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand.

Zhenyu Cai (Z)

Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. drcaizhenyu@tongji.edu.cn.
College of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, Yinchuan, China. drcaizhenyu@tongji.edu.cn.
State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. drcaizhenyu@tongji.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH